Updating the clinical experience in endometriosis--the European perspective

D. R. Bromham, Bromham Dr, Booker MW, Michael Booker, M W Booker, G. L. Rose, Gillian Rose, Rose GL, Peter G. Wardle, Wardle PG, P G Wardle, Richard Newton, J. R. Newton, Newton JR
British journal of obstetrics and gynaecology · 1995 · vol. 102(s12) , pp. 12–16 · doi:10.1111/j.1471-0528.1995.tb09160.x · PMID:7577849 · W3151258878
RCT OA: closed CC0 ⤵ 22 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

A study compared danazol and gestrinone for endometriosis treatment, finding both improved symptoms and showed similar tolerability, though gestrinone caused more hirsutism and danazol more leg cramps.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In a large, double-blind, multicentre study, 269 patients with confirmed endometriosis were randomly allocated to receive either danazol (200 mg twice daily; n = 137) or gestrinone (2.5 mg twice weekly; n = 132) for 6 months. The two groups were comparable in terms of the staging of endometriosis by the American Fertility Society (1979) score. After the sixth month of treatment, repeat laparoscopy was performed. Clinical assessment, haematological and biochemical investigations were carried out during the 6 months of treatment and for a further 12 months' follow-up and are compared between the two groups. A total of 15 patients from the gestrinone group, including four patients with hirsutism, and 17 patients from the danazol group, including six patients with headache, withdrew because of adverse symptoms. An additional 22 patients, including 10 from the gestrinone group and 12 from the danazol group withdrew because of lack of efficacy, pregnancy, elevated hepatic function tests or for reasons unrelated to the trial. Total American Fertility Society scoring showed an improvement of 73.3% in 101 patients receiving gestrinone and 72.7% in 99 patients receiving danazol. The results showed a significant reduction in the severity of dysmenorrhoea by the third month in the danazol group and at 6 months in both groups. There was a significant (P < 0.001) increase in weight observed in both groups during treatment. Overall, the tolerability of danazol and gestrinone was good; however, significantly more patients with gestrinone complained of hirsutism while significantly more with danazol complained of leg cramps. During the 12 months of follow-up, mild, moderate or severe degrees of lower abdominal pain, dysmenorrhoea and deep dyspareunia all fluctuated, with no statistically significant increase in frequency in either group.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrheadyspareunia

MeSH descriptors

Danazol Endometriosis Gestrinone Danazol Danazol Danazol Double-Blind Method Double-Blind Method Endometriosis Endometriosis Female Female Gestrinone Gestrinone Gestrinone Humans Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (5)

Cited by (22)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:58:54.395363+00:00
License: CC0 · commercial use OK